Oncostatin M: Risks and benefits of a Novel Therapeutic Target for Atherosclerosis

CONCLUSION: While OSM may be of therapeutic value in atherosclerosis, drug development should also focus on de-risking the herein identified major safety concerns: tissue remodeling, angiogenesis, bleeding, anemia, and NMDA- and glutamate-induced neurotoxicity. Close monitoring and/or exclusion of patients with various comorbidities may be required for optimal therapeutic benefit.PMID:35959619 | DOI:10.2174/1389450123666220811101032
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research